Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06282458 · ClinicalTrials.gov registry record · Phase 2
Dose-Finding Study Evaluating Effect on Body Composition of Enobosarm in Patients Taking a GLP-1 for Chronic Weight Mgmt
A Phase 2 study, sponsored by Veru.
- Completed
- Registry status
- Phase 2
- Development phase
- 168
- Enrollment target
NCT06282458 is a Phase 2 study that has completed, run by Veru. The registered enrollment target is 168 participants.
The verdict
NCT06282458, a Phase 2 study, has completed, sponsored by Veru.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 168 participants
- Enrollment target
Study Summary
The primary objective of this study is to assess the effect of enobosarm on total lean mass as measured by DEXA in patients maintained on GLP-1 receptor agonists.
Interventions
- DRUG Semaglutide
- DRUG Enobosarm
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 168 participants |
| Start Date | 2024-04-29 |
| Est. Completion | 2025-08-22 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06282458
The ClinicalTrials.gov registry entry for NCT06282458 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 168 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Veru, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Semaglutide is the first listed.
NCT06282458 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06282458 about?
NCT06282458 is a clinical study titled "Dose-Finding Study Evaluating Effect on Body Composition of Enobosarm in Patients Taking a GLP-1 for Chronic Weight Mgmt". The primary objective of this study is to assess the effect of enobosarm on total lean mass as measured by DEXA in patients maintained on GLP-1 receptor agonists.
What is the current status of trial NCT06282458?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 168 participants. The study started on 2024-04-29. Estimated completion is 2025-08-22.
What interventions are being tested in trial NCT06282458?
The interventions under investigation include: Semaglutide (DRUG), Enobosarm (DRUG).
Who is sponsoring clinical trial NCT06282458?
This trial is sponsored by Veru, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.